New data on PD-L1 inhibitor activity and determinants of outcomes in immunotherapy-treated patients - memoinOncology
Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey - Käsmann - Translational Lung Cancer Research
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial - Journal of Thoracic Oncology
Journal club: Durvalumab as Consolidation therapy in Advanced NSCLC
ESMO 2020: Durvalumab Demonstrates Sustained Overall Survival in Unresectable Stage III NSCLC - Onco'Zine
Stage III NSCLC Clinical Trials & Efficacy Data for IMFINZI® (durvalumab)
Cancers | Free Full-Text | Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting | HTML
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial - Journal of Thoracic Oncology
![Lung Cancer - Oncology MDNews by ['mediPr]](https://oncology.medi-paper.com/wp-content/uploads/2021/03/Phase-2-Clinical-Trial-of-Stereotactic-Body-Radiation-Therapy-for.png "Lung Cancer - Oncology MDNews by ['mediPr]")
Lung Cancer - Oncology MDNews by ['mediPr]
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial - Annals of Oncology
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▽, AstraZeneca UK Limited) | British Journal of Cancer
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Innovación en terapia sistémica de cáncer de pulmón
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer - Lung Cancer
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▽, AstraZeneca UK Limited) | British Journal of Cancer
PDF) Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
PDF) PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial - Annals of Oncology
Durvalumab Improves Overall Survival in NSCLC After Chemoradiotherapy - Onco Americas
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study - The Lancet Oncology
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC - Journal of Thoracic Oncology
